With most previous studies on ocular myasthenia gravis stemming from investigations the neurology field, the present investigators came to their conclusion via neuro-ophthalmic analysis.
In the absence of a standardized definition of ocular myasthenia gravis (OMG) from established diagnostic criteria, researchers of a new retrospective, single-center study say that OMG should be considered in patients with both ptosis and diplopia, particularly vertical diplopia.
Further, they suggest that high acetylcholine receptor auto-antibody (AchR Ab) titer, severe ocular symptoms, and abnormal thymic lesions may be associated with poor prognosis and secondary general MG (GMG). They published their findings in Medicine (Baltimore).
“Approximately 50% to 60% of patients with MG initially present with ocular symptoms such as ptosis, diplopia, and ophthalmoplegia. Moreover, 50% to 60% of patients presenting with OMG subsequently progress to GMG, commonly within the first 1 to 2 years,” commented the researchers. “Thus, early changes are readily detected by ophthalmologists in many patients. However, the diagnosis of OMG based on clinical findings is often challenging because OMG should be considered in the differential diagnosis of any pattern of painless, unilateral or bilateral, pupil-sparing ophthalmoplegia with or without ptosis.”
The researchers followed 28 patients with ptosis and/or diplopia for at least 6 months, all of whom were AchR Ab–positive or responded to an antimyasthenic regimen. Throughout follow-up, the researchers found that 18 patients had positive OMG results, 16 of whom were seropositive for AchR Ab and 2 of which were seronegative with positive repetitive nerve stimulation test findings. All 8 patients who had both ptosis and diplopia and all 7 patients with abnormal thymic lesions had positive results.
Abnormal thymic lesions were also more common among patients with AchR Ab titer over 5 nmol/L than among patients with AchR Ab titer under 5 nmolo/L (66.67% vs 11.11%). Among the 18 patients who had positive results, half had an AchR Ab titer under 5 nmol/L and half had an AchR Ab titer over 5 nmol/L. Both horizontal and vertical diplopia was significantly higher in patients with AchR Ab titer over 5 nmol/L.
“Interestingly, all patients had normal thymus without any abnormal thymic lesions (thymus hyperplasia, thymoma) in the negative-result OMG group. This result suggests that thymic lesions are associated with a positive AchR Ab,” explained the researchers. “The negative result group had milder symptoms with a normal thymus and responded well to pyridostigmine treatment. Some patients in this group might have had other types of Abs. A recent study evaluated 62 GMG patients who were MG seronegative for AchR Ab and found that 27.4% of patients were positive for Musk (Muscle-specific tyrosine kinase) Ab and 3.2% for LRP4 (LDL-related receptor-related protein 4) Ab.”
The researchers also compared ocular symptoms between the group of patients with both ptosis and diplopia and patients with one or the other. They found that patients with both symptoms were more likely to have horizontal and vertical diplopia (75% vs 7.14%), experience GMG conversion, and need steroids than patients with ptosis or diplopia. The grade of ptosis, angle of deviation, AchR Ab titer, and ice test results were not significantly different between the groups.
“The strength of this study is the clinical data on ocular symptoms provided by neuro-ophthalmologists in a standardized pattern and information on clinical examination from a single institution,” the study investigators concluded. “after excluding of cranial nerve palsy, if there is ptosis and diplopia, especially vertical diplopia, the possibility of OMG should be considered.”
Reference
Kim D, Roh H, Oh S. Ophthalmologic clinical features of ocular myasthenia gravis. Medicine. 2023;102(2):e31972. doi:10.1097/MD.0000000000031972
Interstitial Lung Abnormalities in Patients With COPD Linked to Cancer, Heart Failure Risks
October 23rd 2024Interstitial lung abnormalities (ILAs) in patients with chronic obstructive pulmonary disease (COPD) are linked to lower lung adenocarcinoma rates but higher rates of other cancers and heart failure.
Read More
Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value
July 18th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.
Listen
FIT Completion, Yield Rates in CRC Screening Similar After New Screening Guidelines
October 22nd 2024Patients were found to have similar completion and yield rates for the fecal immunochemical test (FIT) at both 45 years and 50 years, making screening for colorectal cancer (CRC) effective in younger patients.
Read More
From Polypharmacy to Personalized Care: Dr Nihar Desai Discusses Holistic Cardiovascular Care
May 30th 2024In this episode of Managed Care Cast, Nihar Desai, MD, MPH, cardiologist and vice chief of Cardiology at the Yale School of Medicine, discusses therapies for cardiovascular conditions as they relate to patient adherence, polypharmacy, and health access.
Listen
The Latest in New and Emerging Therapies in Schizophrenia: Dr Megan Ehret
October 22nd 2024In addition to Cobenfy being approved for schizophrenia, there are other drugs with novel mechanisms being studied that may mean combination therapies or, at least, more options for patients in the future.
Read More
Delayed Diagnoses, Oxygen Therapy Use Linked to Worse Outcomes in Patients With Fibrotic ILD
October 21st 2024Posters presented at the CHEST 2024 annual meeting revealed that delays in diagnosing fibrotic interstitial lung disease (ILD) can negatively impact overall survival, while supplemental oxygen therapy may exacerbate clinical burdens through increased rates of acute exacerbations and hospitalizations.
Read More